Literature DB >> 3522806

Intraneuronal IgG in the central nervous system.

R H Fabian, T C Ritchie.   

Abstract

The rat central nervous system was examined immunocytochemically for the presence of endogenous IgG. Examination of representative sections of the neuraxis revealed specific staining for IgG in the pia mater and pial vasculature, the ependyma, and diffusely in the hypothalamus and area postrema where the blood-brain barrier is permeable to large molecules. In addition, intraneuronal staining for IgG was noted in specific nuclei including the ventral horn nuclei and intermediolateral nuclei of the spinal cord, the dorsal motor nucleus of the vagus, the nucleus ambiguous, the motor nucleus of the trigeminal, the hypoglossal, facial, and oculomotor nuclei, nuclei projecting to the pituitary and area postrema, and Purkinje cells. The uptake of immunoglobins by these cell groups may have important implications for the pathogenesis of motor and autonomic neuropathies and neuropathies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3522806     DOI: 10.1016/0022-510x(86)90150-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  15 in total

Review 1.  Passage of intravenous immunoglobulin and interaction with the CNS.

Authors:  U Wurster; J Haas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

2.  Characterization of the Antibody Response after Cervical Spinal Cord Injury.

Authors:  Antigona Ulndreaj; Apostolia Tzekou; Andrea J Mothe; Ahad M Siddiqui; Rachel Dragas; Charles H Tator; Emina E Torlakovic; Michael G Fehlings
Journal:  J Neurotrauma       Date:  2016-12-21       Impact factor: 5.269

3.  Autoantibodies directed against glutamate decarboxylase interfere with glucose-stimulated insulin secretion in dispersed rat islets.

Authors:  Varun Kamat; Jared R Radtke; Qingxun Hu; Wang Wang; Ian R Sweet; Christiane S Hampe
Journal:  Int J Exp Pathol       Date:  2022-03-04       Impact factor: 2.793

Review 4.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

5.  Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immunotherapeutics.

Authors:  Kenneth E Hill; Susan A Clawson; John W Rose; Noel G Carlson; John E Greenlee
Journal:  J Neuroinflammation       Date:  2009-10-29       Impact factor: 8.322

Review 6.  Tau-based treatment strategies in neurodegenerative diseases.

Authors:  Anja Schneider; Eckhard Mandelkow
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

7.  Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction.

Authors:  S H Appel; J I Engelhardt; J García; E Stefani
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

Review 8.  'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

Review 9.  'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

10.  Allergy influences the inflammatory status of the brain and enhances tau-phosphorylation.

Authors:  Heela Sarlus; Caroline Olgart Höglund; Bianka Karshikoff; Xiuzhe Wang; Mats Lekander; Marianne Schultzberg; Mircea Oprica
Journal:  J Cell Mol Med       Date:  2012-10       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.